FMW Media Works Corp.'s New to the Street, a nationally broadcasted business television production, announces airing Episode 556 on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT.

New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:

1). Biopharmaceutical - Tonix Pharmaceuticals, Inc.'s (NASDAQ: TNXP) ($TNXP) interview with Dr. Seth Lederman, MD, Chairman and CEO.

2). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.

3). Decentralized Supercomputing – Dynex's (CRYPTO: DNX) ($DNX) interview with Clifford Mapp, an Independent Expert and Blockchain Pioneer.

4). "The Business of Blockchain" segment with TV Host Jane King - Topic: "Bitcoin Mining and Energy Solutions," sponsored by Bitdeer Technology Group, Inc. (NASDAQ: BTDR) ($BTDR); interviews with Elliot David, Head of Climate Strategy at Sustainable Bitcoin Protocol, and Samantha Robertson, Director of Commercial Strategy at Bitdeer Technology Group, Inc.

5). Stock Blockchain Trading Platform – BlackStar Enterprise Group, Inc.'s (OTCPINK: BEGI) ($BEGI) interview with Joesph Kurczodyna, CEO.

Episode 556

From the Nasdaq MarketSite Studio, Dr. Seth Lederman, MD, Chairman and CEO of Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) ("Tonix"), talks with New to The Street's TV Host Jane King about the Company's successful completion of  Phase 3 studies on its fibromyalgia drug. Tonix's new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia. The drug is a non-opioid, non-addictive painkiller. Since 2009, there have been no new fibromyalgia drugs available in the marketplace. Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in the treatment success. Competitor drugs cause sleeplessness and low energy. Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish fatigue in patients. The side effects are minimal, with around 3% of patients experiencing headaches and some drowsiness. Administered as a sublingual tablet, Tonmya™ has caused tongue numbness in a very limited number of patients. Patients take the drug at bedtime, which can block brain signals that are often associated with pain, and the drug has shown improved sexual functionality. Dr. Ledermen expects the Company to submit its full report to the FDA for market approval sometime during the first half of 2024, with a full approval expectation sometime in 2025. The on-screen QR code is available during the shows; download or visit Tonix Pharmaceuticals, Inc. - https://www.tonixpharma.com/.

New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections. David updates viewers on the Company's FDA  Phase 2 clinical trial on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3. The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results. Phases 2a and 2b confirmed that the drug had approximately 94% success with no reinfections. In treated patients, the microbiome bacteria found in the digestive tract shows the bacteria maintaining and restoring itself within those patients after a 10-day treatment. At a recent microbiome conference presentation in Texas, the Company compared logarithmic results from a competitor drug (vancomycin) to its Ibezapolstat drug, showing the differences in the effects on gut microbiome bacteria. Competitor drugs have been used for decades to treat CDI, but the reinfection rates are very high and greatly diminished gut microbiome bacteria. ACXP's Ibezapolstat study results have shown to combat reinfections effectively. Based on the data and other publications regarding the market size for newly discovered and effective treatment of CDI, ACXP believes Ibezapolstat could be a market worth over $1B. Decades-old antibacterial drugs are not working due to changes in the molecular composition of CDI. Thousands of people worldwide die annually, with many catching CDI in hospitals and nursing homes. Acurx Pharmaceuticals, Inc. believes its Ibezapolstat drug is the next generation for effectively treating CDI. Throughout 2024, Investors and others should expect more exciting news about Ibezapolstat and other positive corporate ongoings. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. - https://www.acurxpharma.com/.

New to The Street's TV Host Jane King interviews Clifford Mapp, an independent expert and blockchain pioneer, who talks about Dynex (CRYPTO: DNX) ($DNX). As a decentralized supercomputer platform, Dynex's ecosystem is transforming and distributing the supercomputer and software industries. Clifford explains that only a handful of corporations and individuals can access supercomputers. Dynex aims to make supercomputer computation affordable, easy to use, and available to everyone and every industry. Over the next 6-12 months, Dynex expects its ecosystem to continue to mature through more network access growth and end-users. With current supercomputing access, Clifford anticipates that the Dynex Marketplace can possibly break world records on computational data. If such an event occurs, Clifford expects a considerable influx of end-users as a newly discovered technology platform. With speed, efficiencies, affordability, and access, end-users can obtain problem-solving solutions with Dynex's supercomputer services. The Company has an aggressive and talented staff of individuals determined to make Dynex's ecosystem user-friendly and will continue to roll out new technology innovations. Dynex allows individual and industry end-users access to supercomputers, providing them with complex quantum-level computation solutions at a fraction of the cost. There is no need for end-users to spend millions of dollars on hardware/software. The on-screen QR code is available during the show; download or visit Dynex - https://dynexcoin.org/.

From the Nasdaq MarketSite Studio, Bitdeer Technology Group, Inc. (NASDAQ: BTDR) ($BTDR) ("Bitdeer") sponsors New to The Street's "The Business of Blockchain" segment. TV Host Jane King is with guests Elliot David, Head of Climate Strategy at Sustainable Bitcoin Protocol (SBP), and Samantha Robertson, Director of Commercial Strategy at Bitdeer Technology Group, Inc., discussing the topic: "Bitcoin Mining and Energy Solutions." Wind, solar, hydro, new crypto mining techniques/technology, and market powers have significantly changed the Bitcoin mining industry's business practices and operational models. Eillot David explains that Bitcoin mining is a data center industry designed and organized to protect and secure the Bitcoin network. Miners constantly seek to become "Carbon Neutral" through innovations and renewable energy methods. Bitcoin mining is not energy intensive, as many believe it to be. The energy usage is around 145 terawatts, about 0.25% of global emissions. Bitcoin mining has a small carbon footprint compared to other industries, like cement, which produces high carbon emissions. Bitcoin mining's approach to decarbonization makes it one of the friendliest climate asset-class industries. Samantha, an executive at Bitdeer, the segment's sponsor, gives some historical insight into the Company's Founder/Chairman, Jihan Wu. She described him as the "Waren Buffet of Bitcoin," a visionary and expert in understanding the Bitcoin commodity marketplace. Under his leadership, Bitdeer has 6-data centers globally: three in the USA, two in Norway, and one in Bhutan. One of the Company's centers is in Texas, a state with the highest percentage of renewable energy creation. The Country of Bhutan is one of the largest sustainable hydroelectric renewable energy producers globally. In Norway, Samantha explains how Bitdeer's data center recycles the heat byproduct to provide energy for nearby greenhouses to produce food. Eliott talks about the partnership between Bitdeer and SBP, working with miners to access clean energy sources. SBP will access a miner's energy source to determine the % of renewable source inputs. After 3rd party validations, Proof-of-Work (POW), and other transparencies, SBP will issue a Sustainable Bitcoin Certificate (SBC), utilized or sold to enhance further end-users and investors to reach ESG goals. SBP is not like a carbon credit that expires after being used to offset a carbon footprint; it's a transferable asset representing one bitcoin's sustainability. So, miners get 2-assets, BTC and SBC. Sustainable Bitcoin Protocol turns environmental sustainability into an appreciating commodity, supporting clean energy Bitcoin miners. Together, Bitdeer and SBP are innovators in the consent evolutionary Bitcoin marketplace.

Joseph Kurczodyna, CEO of BlackStar Enterprise Group, Inc. (OTCPINK: BEGI) ($BEGI), from the Nasdaq MarketSite Studio, sits with New to The Street's TV Host Jane King. BEGI created a digital blockchain platform to revolutionize three financial sectors: digital trading, capital raises, and corporate governance. Joseph talks about pending patents, its recently issued 20-year US Patent, and its significance for the Company's business. With the USSEC giving Bitcoin ETF approvals, the marketplace is opening for more blockchain innovations. BEGI created its BlackStar Digital Trading Platform (BDTP™), a centralized blockchain platform for digitally trading public companies' stocks. Joseph approached the USSEC about the platform a few years ago, and the USSEC approved him to develop a demo platform to show how the blockchain concept works. It took him two years to build the demo, and then the USSEC took two more years to review the demo platform. The Company made a complete 1933 Registration Statement (FORM S-1), fully outlining the Company's business, which was approved in July 2023 by the USSEC. BDTP™ is a centralized blockchain that can fully integrate into a stockbroker’s trading platform, meeting or exceeding US SEC and FINRA regulatory requirements and trading compliances. BEGI can operate without human interaction, with the blockchain recording all trade transactions. In the future, the Company would like to have its blockchain platform run on Global X, a fully automated stock trading platform. The Company will recapitalize itself and seek strategic partners to mainstream its platform. Viewers can learn more by visiting the BlackStar Enterprise Group, Inc.'s website, https://blackstareg.com/.

About Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP):

Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) ("Tonix") is a biopharmaceutical company focused on commercializing, developing, discovering, and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system disorders. Tonix's priority is to submit a New Drug Application (NDA) to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia. Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024. TNX-102 SL is being developed to reduce the severity of acute stress reaction and the frequency of acute stress disorder and posttraumatic stress disorder. This trial is being sponsored by the University of North Carolina and received funding support from the U.S. Department of Defense. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and top-line results from a proof-of-concept study were reported in the third quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA and received funding from the National Institute on Drug Abuse (NIDA). A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024. Tonix's rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome (PWS). The FDA has granted TNX-2900 Orphan Drug designation, and an investigational new drug (IND) application has been cleared to support a Phase 2 study in PWS patients. Tonix's immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 was initiated in the third quarter of 2023. Tonix's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. During the fourth quarter of 2023, TNX-1800 was selected by the U.S. National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Project NextGen for inclusion in Phase 1 clinical trials. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.(*Tonix's product development candidates are investigational new drugs or biologics and have not been approved for any indication;  Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.) - https://www.tonixpharma.com/.

About Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP):

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) is a clinical-stage biopharmaceutical Company focused on developing new antibiotics for difficult-to-treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and drug-resistant Streptococcus pneumoniae (DRSP). The Company's Ibezapolstat is a novel, orally administered antibiotic developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial.  It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.  Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria species, appears to contribute to maintaining a healthy gut microbiome. The Company completed Phase 2 clinical trials of Ibezapolstat. To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.

About Dynex (CRYPTO: DNX) ($DNX):

Dynex (CRYPTO: DNX) ($DNX) represents a cutting-edge neuromorphic computing platform built upon a revolutionary adaptable blockchain system. This decentralized neuromorphic supercomputing network executes calculations with unparalleled speed and efficiency, surpassing quantum computing limitations. Dynex is the world's first neuromorphic supercomputing blockchain based on its DynexSolve chip algorithm, a Proof-of-Useful-Work (PoUW) approach to solving real-world problems. PoUW miners participate on a decentralized network that can sometimes perform tasks at speeds greater than quantum computing. In December 2023, the Company officially launched the Dynex Marketplace - https://dynexcoin.org/.

About Bitdeer Technology Group, Inc. (NASDAQ: BTDR) ($BTDR) ("Bitdeer")  

Bitdeer Technology Group, Inc. (NASDAQ: BTDR) ("Bitdeer") is a world-leading technology company for blockchain and high-performance computing. Bitdeer is committed to providing comprehensive computing solutions for its customers. Bitdeer handles complex processes involved in computing, such as equipment procurement, transport logistics, data center design and construction, equipment management, and daily operations. Bitdeer also offers advanced cloud capabilities to customers with high demand for artificial intelligence. Headquartered in Singapore, Bitdeer has deployed data centers in the United States, Norway, and Bhutan - https://www.bitdeer.com/.

About Sustainable Bitcoin Protocol (SBP):

Sustainable Bitcoin Protocol (SBP) has created a new environmental commodity that incentivizes clean energy Bitcoin miners and allows investors to reach their ESG goals while owning Bitcoin. SBP is on a mission to lead the sustainable Bitcoin revolution. The Company is unlocking Bitcoin's unique potential to become the most transparent and sustainable asset by creating a new environmental commodity derived from verified clean energy mining - https://www.sustainablebtc.org/.

About BlackStar Enterprise Group, Inc. (OTCPINK: BEGI) ($BEGI):

Blackstar Enterprise Group, Inc. (OTCPINK: BEGI) ($BEGI) is a public company that shares trade on the OTC Markets. The Company is developing a unique blockchain trading system for registered securities using Distributed Ledger Technology (DLT) and Web 3.0 ecosystem protocols. This revolutionary software platform is called the BlackStar Digital Trading Platform™ ("BDTP™"), a trading platform for electronic fungible shares in book-entry, and compliant at any US Brokerage Firm. The platform drops into the compliant US Broker-Dealer trading system and acts as a spot market that only accepts cash and free-trading securities without allowing any short selling. Once BDTP TM is live, after SEC and FINRA approvals, BlackStar intends to market the platform to other publicly traded companies as a subscription service with an issuer-specific customizable interface - https://blackstareg.com/.

About New to The Street:

New to The Street is an FMW Media production that operates one of the longest-running US and International sponsored and syndicated Nielsen-rated programming television brands, "New to The Street." Since 2009, New to The Street has run biographical interview segment shows across major U.S. television networks. The Nielsen-rated and sponsored broadcast programming platform reaches millions of homes in the US and international markets. FMW's New to The Street show appears on Bloomberg and the FOX Business Network as sponsored programming. FMW is also one of the nation's largest buyers of linear television, long and short-form paid programming - https://www.newtothestreet.com/.

Forward-Looking Statements Disclaimer US/Canada:

This press release contains forward-looking statements within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. Forward-looking statements do not guarantee future performance or results and will not necessarily be accurate indications of when such performance or results are achieved. This press release should be considered in all filings of the Companies contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as "seek," "anticipate," "believe," "plan," "estimate," "expect," "likely," and "intend" and statements that an event or result "may," "will," "should," "could" or "might" occur or be achieved and other similar expressions. These statements reflect management's current beliefs and are based on information currently available to management as of the date hereof. Forward-looking information in this press release includes, without limiting, the foregoing expectations. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

FMW Media Contact:Monica Brennanmonica@NewtoTheStreet.com1-917-330-2564

"New to The Street" Business Development Office1-516-696-5900Support@NewToTheStreet.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e605f857-37f4-4dd7-b4fb-c8027b79778e

Tonix Pharmaceuticals (NASDAQ:TNXP)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 4월(4) 2024 Tonix Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Tonix Pharmaceuticals (NASDAQ:TNXP)
과거 데이터 주식 차트
부터 4월(4) 2023 으로 4월(4) 2024 Tonix Pharmaceuticals 차트를 더 보려면 여기를 클릭.